Transient corneal thinning in eyes undergoing corneal cross-linking

Am J Ophthalmol. 2011 Oct;152(4):533-6. doi: 10.1016/j.ajo.2011.03.023. Epub 2011 Jul 2.

Abstract

Purpose: To report the corneal thinning during and after corneal cross-linking (CXL).

Design: Prospective, nonrandomized, single-center observational study.

Methods: Thirty patients (30 eyes; 9 female, 21 male; age, 38 ± 12 years) were consecutively scheduled for CXL between January 23 and July 6, 2009. Twenty-four eyes had progressive keratoconus, 2 had pellucid marginal degeneration, 3 eyes had progressive keratectasia after a LASIK operation, and 1 eye had pseudophakic bullous keratopathy. Riboflavin-ultraviolet A (UVA)-induced CXL included the instillation of 0.1% riboflavin drops for 30 minutes followed by riboflavin instillation combined with UVA irradiation for another 30 minutes. Corneal thickness was measured preoperatively, during CXL, and after 1 and 6 months using an ultrasound pachymeter. Changes in the endothelial cell count, corneal steepness, refraction, and visual performance are also given.

Results: On average, the corneas thinned 87 ± 40 μm (range, 37-206 μm; 19% ± 7%) during a 60-minute CXL treatment. In 1 patient, the cornea did not swell, even with hypotonic solution such that CXL would be safe. After 1 month, the corneal thickness was lower than the preoperative thickness, but after 6 months, the corneas had regained their original thicknesses. The endothelial cell count and corneal steepness were unchanged after CXL. The UCVA (uncorrected visual acuity) and BSCVA (best spectacle-corrected visual acuity) were improved 6 months after CXL.

Conclusions: Corneal thickness decreases significantly during CXL, even to a level where the health of the endothelium and cornea is jeopardized. Visual performance is improved 6 months after CXL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Body Weights and Measures
  • Cell Count
  • Collagen / metabolism
  • Cornea / diagnostic imaging
  • Cornea / pathology*
  • Corneal Diseases / etiology*
  • Corneal Stroma / metabolism
  • Cross-Linking Reagents / therapeutic use*
  • Endothelium, Corneal / pathology
  • Female
  • Humans
  • Intraoperative Complications*
  • Male
  • Photosensitizing Agents / therapeutic use*
  • Postoperative Complications*
  • Prospective Studies
  • Riboflavin / therapeutic use*
  • Ultrasonography
  • Ultraviolet Rays
  • Visual Acuity / physiology

Substances

  • Cross-Linking Reagents
  • Photosensitizing Agents
  • Collagen
  • Riboflavin